LakhaniSREllisIOSchnittSJ. World Health Organization Classification of Tumours of the Breast. 4th ed.Lyons, France: International Agency for Research on Cancer; 2012.
AllredDCAndersonSJPaikS. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen-receptor positive ductal carcinoma in situ: a study based on NSABP Protocol B-24. J Clin Oncol2012;30:1268–1273.
FisherBDignamJWolmark. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet1999;353:1993–2000.
CarlsonRWAndersonBOBensingerW. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2010. Accessed March 20 2015. To view the most recent version of these guidelines visit NCCN.org.
MargoleseRGCecchiniRSJulianTB. Primary results, NRG Oncology/NSABP B-35: a clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIs undergoing lumpectomy plus radiation [abstract]. J Clin Oncol2015;33(Suppl):Abstract LBA 500.
Cuncins-HearnABoultMBabidgeW. National Breast Cancer Audit: ductal carcinoma in situ management in Australia and New Zealand. ANZ J Surg2007;77:64–68.
YenTWHuntKKMirzaNQ. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer2004;100:942–949.
NakhlisFLazarusLHouN. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b invasive carcinoma. J Am Coll Surg2005;201:688–694.
ZujewskiJAHarlanLCMorrellDM. Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Res Treat2011;127:251–257.
NCCN Member Institutions. Available at: https://www.nccn.org/members/network.aspx. Accessed May 28 2015.
NCI-Designated Cancer Centers. Available at: cancer.gov/research/nci-role/cancer-centers. Accessed May 28 2015.
California Cancer Registry. Available at: http://ccrcal.org. Accessed December 21 2014.
RhoadsKFPatelMIMaYSchmidtLA. How do integrated health care systems address racial and ethnic disparities in colon cancer?J Clin Oncol2015;8:854–860.
North American Association of Central Cancer Registries. US Registries Certified in 2013 for 2010 Incidence Data. Available at: http://www.naaccr.org/Certification/USCert2010.aspx. Accessed May 24 2015.
YangJSchuppCWHarratiA. Developing an area-based socioeconomic measure from American Community Survey data. Fremont, CA: Cancer Prevention Institute of California; 2014. Available at: http://www.cpic.org/files/PDF/Research_Files/Reports/CPIC_ACS_SES_Index_Documentation_3-10-2014.pdf. Accessed July 25 2016.
YostKPerkinsCCohenR. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control2001;12:703–711.
Office of Statewide Health Planning and Development. Available at: http://www.oshpd.ca.gov/AboutUs.html. Accessed March 9 2015.
California Cancer Reporting System Standards Volume I: Abstracting and Coding Procedures for Hospitals. Available at: http://ccrcal.org/DSQC_Pubs/V1_2013_Online_Manual/index.htm. Accessed July 25 2015.
GradisharWJAndersonBOBalassanianR. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2015. Accessed March 20 2015. To view the most recent version of these guidelines visit: http://www.nccn.org.
WapnirILDignamJJFisherB. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NASBP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst2011;103:478–488.
YenTWKuererHMOttesenRA. Impact of randomized clinical trial results in the National Comprehensive Cancer Network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol2007;25:3251–3258.
RutterCEParkHSKilleleaBKEvansSB. Growing use of mastectomy for ductal carcinoma-in-situ of the breast among young women in the United States. Ann Surg Oncol2015;22:2378–2386.
ShanjunLLaxminarayanR. Are physicians' prescribing decisions sensitive to drug prices? Evidence from a free-antibiotics program. Health Econ2015;24:158–174.
RibieCSargentDMooreM. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med2003;349:247–257.
BaileySRSapersteinAPennerAM. Race, color, and income inequality across the Americas. Demographic Research2014;31:735–756. Available at: http://www.demographic-research.org/volumes/vol31/24/31-24.pdf. Accessed July 25 2016.
MargoleseRGCecchiniRSJulianTB. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet2016;387:849–856.
HadjiP. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol2010;73:156–166.
MeguerditchianANStewartARoistacherJ. Claims data linked to hospital registry data enhance evaluation of the quality of care of breast cancer. J Surg Oncol2010;101:593–599.